Fisher & Paykel Healthcare Corporation (ASX:FPH) remains a global healthcare technology company focused on respiratory care products, including devices used in hospitals and homecare settings.

The New Zealand-based company continues to benefit from Demand for respiratory support solutions, with a Business model supported by both equipment sales and recurring consumable products.

Company Overview

Fisher & Paykel Healthcare designs, manufactures and supplies respiratory care products used in hospitals and homecare environments.

Its product portfolio includes respiratory humidification systems, nasal high flow therapy devices, patient interfaces and obstructive sleep apnoea masks.

The company operates across two main areas: Hospital, which serves acute care settings, and Homecare, which focuses on sleep apnoea and respiratory support outside hospitals.

FY26 Performance

Fisher & Paykel Healthcare reported its FY26 results for the year ended 31 March 2026, showing continued growth across its operations.

Operating revenue increased to NZ$2.31 billion, while net profit after tax rose to NZ$468.5 million.

The company reported growth across both Hospital and Homecare segments, supported by demand for respiratory products and ongoing product development.

Business Growth

The company continues focusing on expanding adoption of respiratory care technologies and strengthening its global presence.

Hospital products remain supported by demand for respiratory support solutions in clinical settings, while Homecare products benefit from ongoing demand for sleep apnoea treatment and respiratory management.

Fisher & Paykel Healthcare also continues investing in Manufacturing and product development capabilities.

Operational Focus

The company continues to invest in research and development, manufacturing capacity and product innovation.

Its recurring consumables business remains an important part of its operating model, as many medical devices require ongoing replacement products.

Maintaining product quality, managing production capacity and expanding healthcare adoption remain key operational priorities.

Factors to Watch

Investors are expected to monitor the company’s half-year results, revenue growth and progress against FY27 expectations.

Key areas include demand for respiratory products, healthcare spending trends, manufacturing efficiency and changes in global trade conditions.

The company’s ability to maintain margins while expanding production capacity will also remain important.

Risks

Fisher & Paykel Healthcare operates in competitive medical device markets where regulatory requirements, product approvals and healthcare spending patterns can influence performance.

Currency movements may affect reported results due to its global operations and New Zealand reporting currency.

Changes in trade policies, Supply chain conditions and competition in respiratory care markets may also impact future growth.

Conclusion

Fisher & Paykel Healthcare continues to build its position in respiratory care through a combination of medical devices, consumable products and healthcare technology solutions.

The company’s FY26 performance reflected continued growth, while future results will depend on healthcare demand, operational execution and market conditions. For investors following ASX healthcare stocks, Fisher & Paykel Healthcare remains a company to monitor.